Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Sutro Biopharma Partners with Pfizer on Novel Peptide-Based Therapeutics

By Pharmaceutical Processing | January 7, 2011

Sutro Biopharma, a biopharmaceutical company developing
novel and biosuperior protein therapeutics with improved pharmaceutical
properties, today announced that the company has entered into a multi-year
collaboration with Pfizer for the research, development and commercialization
of novel peptide-based therapeutics.

Under the terms of the agreement, Sutro Biopharma will
receive an upfront payment of an undisclosed amount, and Pfizer will provide
Sutro with ongoing research funding. Sutro is eligible to receive development
milestone payments and royalties upon commercialization of any products that
may result from the collaboration. Additional details of the partnership were
not disclosed.

“We are pleased to enter into this collaboration with Pfizer
because it provides validation for the potential of our technology platform,”
said William Newell, chief executive officer of Sutro Biopharma. “This is
another milestone in the maturation of the company as we move toward
identification of our first drug candidates.”

Sutro Biopharma recently secured $36.5 million in a Series C
financing and announced the appointment of Trevor Hallam, Ph.D., as chief
scientific officer. This is the first major collaboration announced by the
company.

“This partnership gives Pfizer access to peptides that have
been difficult to produce using conventional technologies,” said Jaume Pons,
Ph.D., vice president and chief scientific officer at Pfizer’s Rinat
subsidiary. “Sutro’s open biochemical protein synthesis technology platform
potentially resolves many of the problems inherent in other approaches, and we
are looking forward to the mutual success of our collaboration.”

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards